Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease

by Reshma Anand on  September 5, 2015 at 1:02 PM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

Novartis partners with the California-based biotech company Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches.
Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease
Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease

Novartis stated, "Amgen will make initial payments and cover some research and development costs at the start with regard to the BACE inhibitor program for treatment of Alzheimer's. That will be followed by a 50-50 cost and profit sharing arrangement."

As for migraine, Novartis will fund some R&D expenses for an agreed period and pay Amgen double-digit royalties on sales. The Basel-based company will also receive some commercialization and co-development rights to "the investigative molecules in Amgen's migraine portfolio."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Alzheimers Disease Drug Toxicity Signature Drug Toxicity Top Ten Selling Drugs Genetics of Alzheimer´s disease 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive